Osteopore

Osteopore OCF Margin

The Operating Cash Flow Margin of Osteopore (OSX.AX) as of Oct 28, 2026 is -83.64 %. In the previous year, Operating Cash Flow Margin was -109.84 % — a change of -23.85% (higher).

OCF Margin

-83.64 %

YoY

-23.85%

Last updated:

Operating Cash Flow Margin of Osteopore is 2025 -83.64 % . Operating Cash Flow Margin of Osteopore was 2024 -109.84 % . It decreases by -23.85% higher compared to the previous year.

The Osteopore OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
-35.74 AUD
Jan 1, 2019
-422.35 AUD
Jan 1, 2020
-116.82 AUD
Jan 1, 2021
-341.92 AUD
Jan 1, 2022
-236.20 AUD
Jan 1, 2023
-168.54 AUD
Jan 1, 2024
-109.84 AUD
Jan 1, 2025
-83.64 AUD
The Osteopore OCF Margin history
YEAROCF MarginYoY
-83.64 %-23.85%
-109.84 %-34.83%
-168.54 %-28.65%
-236.20 %-30.92%
-341.92 %+192.68%
-116.82 %-72.34%
-422.35 %+1,081.75%
-35.74 %-2,054.94%
1.83 %-102.03%
-89.99 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Osteopore Stock analysis

What does Osteopore do? Osteopore Ltd. develops and markets bioresorbable polymer implants for neurosurgical, orthopaedic, and maxillofacial surgeries. The company commercializes bespoke products engineered to facilitate bone healing, utilizing patented technology that fabricates micro-structured scaffolds through 3D printing and bioresorbable materials. Key products include Osteoplug in plug and strip configurations for craniotomy gap filling, Osteomesh, and Osteoplug-C for craniofacial applications. These solutions support bone tissue integration from the skull to the bone flap, targeting procedures such as cranioplasty, craniosynostosis, and guided bone regeneration. The company serves medical professionals and healthcare facilities requiring advanced bone regeneration solutions. Its products are designed for specific surgical applications including craniotomy, orbital floor reconstruction, socket preservation, and minimally invasive skull base surgery. Osteopore Ltd. focuses on delivering patient-specific implants (PSI) for cranial and mandibular procedures, alongside solutions for burr hole restoration with shunt drainage systems. These offerings cater to specialized surgical segments demanding precision and biocompatibility. Osteopore Ltd.'s revenue streams derive from the sale of its proprietary implant systems to hospitals and surgical centers. The company’s technology enables the production of custom implants that address complex bone healing needs, particularly in neurosurgery, orthopaedics, and maxillofacial procedures. By providing tailored solutions for cranioplasty, craniosynostosis, and guided bone regeneration, the company meets the demands of healthcare providers seeking effective bone regeneration technologies. Osteopore is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Osteopore stock

Operating Cash Flow Margin of Osteopore is -83.64 % in 2025.

Operating Cash Flow Margin of Osteopore changed from -109.84 % to -83.64 %, representing a -23.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Osteopore since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Osteopore with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Osteopore

All Key Metrics — Osteopore